Patents by Inventor Casey McComas
Casey McComas has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230250102Abstract: The present invention relates to compounds and methods useful for inhibiting the DNA polymerase IIIC enzyme. The invention also provides pharmaceutically acceptable compositions comprising compounds of the present invention and methods of using said compositions in the treatment of Gram-positive bacteria infections.Type: ApplicationFiled: April 11, 2023Publication date: August 10, 2023Inventors: Xiang Y. YU, Li H. XING, Minghua WANG, Casey McCOMAS, Michael SILVERMAN, Richard SOLL
-
Publication number: 20220112195Abstract: The present invention relates to compounds and methods useful for inhibiting the DNA polymerase IIIC enzyme. The invention also provides pharmaceutically acceptable compositions comprising compounds of the present invention and methods of using said compositions in the treatment of Gram-positive bacteria infections.Type: ApplicationFiled: April 2, 2021Publication date: April 14, 2022Inventors: Xiang Y. YU, Li H. XING, Minghua WANG, Casey McCOMAS, Michael SILVERMAN, Richard SOLL
-
Patent number: 11001592Abstract: The present invention relates to compounds and methods useful for inhibiting the DNA polymerase IIIC enzyme. The invention also provides pharmaceutically acceptable compositions comprising compounds of the present invention and methods of using said compositions in the treatment of Gram-positive bacterial infections.Type: GrantFiled: June 15, 2020Date of Patent: May 11, 2021Assignee: Acurx Pharmaceuticals, LLCInventors: Xiang Y. Yu, Li H. Xing, Minghua Wang, Casey McComas, Michael Silverman, Richard Soll
-
Patent number: 10836772Abstract: The present invention relates to compounds and methods useful for inhibiting the DNA polymerase IIIC enzyme. The invention also provides pharmaceutically acceptable compositions comprising compounds of the present invention and methods of using said compositions in the treatment of Gram-positive bacterial infections.Type: GrantFiled: June 15, 2020Date of Patent: November 17, 2020Assignee: Acurx Pharmaceuticals, LLCInventors: Xiang Y. Yu, Li H. Xing, Minghua Wang, Casey McComas, Michael Silverman, Richard Soll
-
Publication number: 20200308179Abstract: The present invention relates to compounds and methods useful for inhibiting the DNA polymerase IIIC enzyme. The invention also provides pharmaceutically acceptable compositions comprising compounds of the present invention and methods of using said compositions in the treatment of Gram-positive bacterial infections.Type: ApplicationFiled: June 15, 2020Publication date: October 1, 2020Inventors: Xiang Y. YU, Li H. XING, Minghua WANG, Casey McCOMAS, Michael SILVERMAN, Richard SOLL
-
Publication number: 20200308180Abstract: The present invention relates to compounds and methods useful for inhibiting the DNA polymerase IIIC enzyme. The invention also provides pharmaceutically acceptable compositions comprising compounds of the present invention and methods of using said compositions in the treatment of Gram-positive bacterial infections.Type: ApplicationFiled: June 15, 2020Publication date: October 1, 2020Inventors: Xiang Y. YU, Li H. XING, Minghua WANG, Casey McCOMAS, Michael SILVERMAN, Richard SOLL
-
Patent number: 10723741Abstract: The present invention relates to compounds and methods useful for inhibiting the DNA polymerase IIIC enzyme. The invention also provides pharmaceutically acceptable compositions comprising compounds of the present invention and methods of using said compositions in the treatment of Gram-positive bacteria infections.Type: GrantFiled: December 19, 2019Date of Patent: July 28, 2020Assignee: Acurx Pharmaceuticals, LLCInventors: Xiang Y. Yu, Li H. Xing, Minghua Wang, Casey McComas, Michael Silverman, Richard Soll
-
Patent number: 7517899Abstract: The present invention is directed to phenylaminopropanol derivatives of formula I: or a pharmaceutically acceptable salt thereof, compositions containing these derivatives, and methods of their use for the prevention and treatment of conditions ameliorated by monoamine reuptake including, inter alia, vasomotor symptoms (VMS), sexual dysfunction, gastrointestinal and genitourinary disorders, chronic fatigue syndrome, fibromylagia syndrome, nervous system disorders, and combinations thereof, particularly those conditions selected from the group consisting of major depressive disorder, vasomotor symptoms, stress and urge urinary incontinence, fibromyalgia, pain, diabetic neuropathy, and combinations thereof.Type: GrantFiled: March 28, 2005Date of Patent: April 14, 2009Assignee: WyethInventors: Callain Younghee Kim, Paige Erin Mahaney, Eugene John Trybulski, Puwen Zhang, Eugene Anthony Terefenko, Casey McComas, Michael Anthony Marella, Richard Dale Coghlan, Gavin David Heffernan, Stephen Todd Cohn, An Thien Vu, Joseph Peter Sabatucci, Fei Ye
-
Publication number: 20080114050Abstract: Pyrrole-oxindole derivatives useful as progesterone receptor antagonists, and methods for preparing the same, are provided. Pharmaceutical compositions containing these derivatives are described, as is the use thereof in contraception and hormone-related conditions.Type: ApplicationFiled: November 16, 2007Publication date: May 15, 2008Applicant: WyethInventors: Andrew Fensome, Casey McComas, Edward Melenski, Michael Marella, Jay Wrobel, Gary Grubb
-
Publication number: 20080064673Abstract: Progesterone receptor modulators of formula I, or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4, R5, R6 and R7 are as defined herein. These compounds are useful for contraception and hormone replacement therapy. Also provided are products containing these compounds.Type: ApplicationFiled: September 12, 2007Publication date: March 13, 2008Applicant: WyethInventors: Casey McComas, Andrew Fensome, Edward Melenski
-
Publication number: 20070072928Abstract: The present invention is directed to substituted propylamine derivatives of formula I: or a pharmaceutically acceptable salt thereof, compositions containing these derivatives, and methods of their use for the prevention and treatment of conditions ameliorated by monoamine reuptake including, inter alia, vasomotor symptoms (VMS), sexual dysfunction, gastrointestinal and genitourinary disorders, chronic fatigue syndrome, fibromylagia syndrome, nervous system disorders, and combinations thereof, particularly those conditions selected from the group consisting of major depressive disorder, vasomotor symptoms, stress and urge urinary incontinence, fibromyalgia, pain, diabetic neuropathy, and combinations thereof.Type: ApplicationFiled: September 27, 2006Publication date: March 29, 2007Applicant: WyethInventors: Casey McComas, Puwen Zhang, Eugene Terefenko, An Vu, Stephen Cohn
-
Publication number: 20070072918Abstract: The present invention is directed to benzothiadiazolylphenylalkylamine derivatives of formula I: or a pharmaceutically acceptable salt thereof, compositions containing these derivatives, and methods of their use for the prevention and treatment of conditions ameliorated by monoamine reuptake including, inter alia, vasomotor symptoms (VMS), sexual dysfunction, gastrointestinal and genitourinary disorders, chronic fatigue syndrome, fibromylagia syndrome, nervous system disorders, and combinations thereof, particularly those conditions selected from the group consisting of major depressive disorder, vasomotor symptoms, stress and urge urinary incontinence, fibromyalgia, pain, diabetic neuropathy, and combinations thereof.Type: ApplicationFiled: September 27, 2006Publication date: March 29, 2007Applicant: WyethInventors: Casey McComas, Puwen Zhang, Eugene Trybulski, An Vu, Eugene Terefenko
-
Publication number: 20070072897Abstract: The present invention is directed to phenylaminopropanol derivatives of formulae I, II, and III: or a pharmaceutically acceptable salt thereof, compositions containing these derivatives, and methods of their use for the prevention and treatment of conditions ameliorated by monoamine reuptake including, inter alia, vasomotor symptoms (VMS), sexual dysfunction, gastrointestinal and genitourinary disorders, chronic fatigue syndrome, fibromyalgia syndrome, nervous system disorders, and combinations thereof, particularly those conditions selected from the group consisting of major depressive disorder, vasomotor symptoms, stress and urge urinary incontinence, fibromyalgia, pain, diabetic neuropathy, schizophrenia, and combinations thereof.Type: ApplicationFiled: September 27, 2006Publication date: March 29, 2007Applicant: WyethInventors: Paige Mahaney, Gavin Heffernan, Richard Coghlan, Stephen Cohn, Callain Kim, Douglas Jenkins, Michael Marella, Casey McComas, Joseph Sabatucci, Eugene Terefenko, Eugene Trybulski, An Vu, Fei Ye, Puwen Zhang
-
Publication number: 20070027201Abstract: The use of compounds of formula I, or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4, R5, R6 and R7, are as defined herein, for contraception, hormone replacement therapy, synchronizing estrus, treating dysmenorrhea, treating dysfunctional uterine bleeding, treating uterine myometrial fibroids, treating endometriosis, treating benign prostatic hypertrophy, treating carcinomas and adenocarcinomas of the endometrium, ovary, breast, colon, prostate, pituitary, and meningioma, inducing amenorrhea, cycle-related symptoms, or treating symptoms of premenstrual syndrome and premenstrual dysphoric disorder are described. Also provided are products containing these compounds.Type: ApplicationFiled: July 27, 2006Publication date: February 1, 2007Applicant: WyethInventors: Casey McComas, Andrew Fensome, Edward Melenski
-
Publication number: 20070027125Abstract: Progesterone receptor modulators of formula I, or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4, R5, R6, and R7 are as defined herein. These compounds are useful for contraception and hormone replacement therapy. Also provided are products containing these compounds.Type: ApplicationFiled: July 27, 2006Publication date: February 1, 2007Applicant: WyethInventors: Casey McComas, Andrew Fensome, Edward Melenski
-
Publication number: 20070027126Abstract: Progesterone receptor modulators of formula I, or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4, R5, R6 and R7 are as defined herein, are useful for contraception and hormone replacement therapy are described. Also provided are products containing these compounds.Type: ApplicationFiled: July 27, 2006Publication date: February 1, 2007Applicant: WyethInventors: Casey McComas, Andrew Fensome, Edward Melenski
-
Publication number: 20060030615Abstract: Pyrrole-oxindole derivatives useful as progesterone receptor antagonists are provided. Pharmaceutical compositions containing these derivatives are described, as is the use thereof in contraception and hormone-related conditions.Type: ApplicationFiled: July 6, 2005Publication date: February 9, 2006Applicant: WyethInventors: Andrew Fensome, Casey McComas, Edward Melenski, Michael Marella, Jay Wrobel
-
Publication number: 20060030717Abstract: Pyrrole-oxindole derivatives useful as progesterone receptor antagonists, and methods for preparing the same, are provided. Pharmaceutical compositions containing these derivatives are described, as is the use thereof in contraception and hormone-related conditions.Type: ApplicationFiled: July 6, 2005Publication date: February 9, 2006Applicant: WyethInventors: Andrew Fensome, Casey McComas, Edward Melenski, Michael Marella, Jay Wrobel, Gary Grubb
-
Publication number: 20060009509Abstract: A method of contraception is provided which involves delivery of 21 to 27 consecutive days of one or more PR antagonists in the absence of a progestin, estrogen, or other steroidal compound, followed by 1 to 7 days without any active agent. Also described is a pharmaceutically useful kit to facilitate delivery of this regimen.Type: ApplicationFiled: July 6, 2005Publication date: January 12, 2006Applicant: WyethInventors: Gary Grubb, Ginger Constantine, Andrew Fensome, Casey McComas, Edward Melenski, Michael Marella, Jay Wrobel
-
Publication number: 20050222148Abstract: The present invention is directed to phenylaminopropanol derivatives of formula I: or a pharmaceutically acceptable salt thereof, compositions containing these derivatives, and methods of their use for the prevention and treatment of conditions ameliorated by monoamine reuptake including, inter alia, vasomotor symptoms (VMS), sexual dysfunction, gastrointestinal and genitourinary disorders, chronic fatigue syndrome, fibromylagia syndrome, nervous system disorders, and combinations thereof, particularly those conditions selected from the group consisting of major depressive disorder, vasomotor symptoms, stress and urge urinary incontinence, fibromyalgia, pain, diabetic neuropathy, and combinations thereof.Type: ApplicationFiled: March 28, 2005Publication date: October 6, 2005Applicant: WyethInventors: Callain Kim, Paige Mahaney, Eugene Trybulski, Puwen Zhang, Eugene Terefenko, Casey McComas, Michael Marella, Richard Coghlan, Gavin Heffernan, Stephen Cohn, An Vu, Joseph Sabatucci, Fei Ye